{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:09Z","timestamp":1792788609874,"version":"4.5.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Amgen Mexico"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aims to assess the cost effectiveness of romosozumab versus teriparatide, both sequenced to denosumab, for the treatment of severe postmenopausal osteoporosis at very high risk of fractures in Mexican women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Markov model was used to assess the relative cost effectiveness of 1 year of romosozumab versus 2 years of teriparatide, both sequenced to denosumab for a total treatment duration of 5 years. Outcomes for a cohort of women with a mean age of 74 years, a T-score \u2264-2.5 and a previous fragility fracture were simulated over a lifetime horizon. The analysis was conducted from the perspective of the Mexican healthcare system and used a discount rate of 5% per annum. To inform relative fracture incidence, the bone mineral density (BMD) advantage of romosozumab over teriparatide was translated into relative risks of fracture, using relationships provided by a meta-regression of osteoporosis therapy trials. Outcomes were assessed in terms of lifetime costs (2023 Mexican pesos), quality-adjusted life years (QALYs) and life-years gained (LYs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Base case results showed that, compared with teriparatide\/ denosumab, romosozumab\/ denosumab reduced costs by $51,363 MXN per patient and yielded 0.03 additional QALYs and 0.01 LYs. Scenario analyses and probabilistic sensitivity analyses confirmed that results are robust to uncertainty in model assumptions and inputs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results show that romosozumab\/ denosumab produces greater health benefits at a lower total cost than teriparatide\/ denosumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0299673","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T13:32:56Z","timestamp":1738935176000},"page":"e0299673","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2836-699X","authenticated-orcid":true,"given":"Juan Pablo","family":"Diaz Martinez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Aubry de Maraumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elly","family":"Natty S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Miguel","family":"Camacho Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"pone.0299673.ref001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"SH Tella","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"pone.0299673.ref002","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11926-010-0097-y","article-title":"The societal burden of osteoporosis.","volume":"12","author":"DJ Becker","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"pone.0299673.ref003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11657-013-0125-4","article-title":"Health care costs of osteopenia, osteoporosis, and fragility fractures in Mexico.","volume":"8","author":"F Carlos","year":"2013","journal-title":"Arch Osteoporos"},{"issue":"2, Supplement 1","key":"pone.0299673.ref004","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0002-9343(97)90022-X","article-title":"The crippling consequences of fractures and their impact on quality of life","volume":"103","author":"C. Cooper","year":"1997","journal-title":"Am J Med"},{"key":"pone.0299673.ref005","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s00198-010-1480-2","article-title":"Mortality rates after incident non-traumatic fractures in older men and women.","volume":"22","author":"S Morin","year":"2011","journal-title":"Osteoporos Int"},{"key":"pone.0299673.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-021-03960-z","article-title":"Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario.","volume":"22","author":"JP Brown","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"pone.0299673.ref007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11657-013-0137-0","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports.","volume":"8","author":"A Svedbom","year":"2013","journal-title":"Arch Osteoporos."},{"issue":"1","key":"pone.0299673.ref008","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2008.092775","article-title":"Clinical subsequent fractures cluster in time after first fractures","volume":"68","author":"TA van Geel","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"pone.0299673.ref009","first-page":"1","volume-title":"Archives of osteoporosis","author":"R Pinedo-Villanueva","year":"2019"},{"key":"pone.0299673.ref010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women.","volume":"30","author":"A Balasubramanian","year":"2019","journal-title":"Osteoporos Int."},{"issue":"1","key":"pone.0299673.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-021-04051-9","article-title":"Fragility fracture identifies patients at imminent risk for subsequent fracture: real-world retrospective database study in Ontario, Canada.","volume":"22","author":"JD Adachi","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"key":"pone.0299673.ref012","volume-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992].","author":"Organization WH","year":"1994"},{"issue":"2","key":"pone.0299673.ref013","first-page":"97","article-title":"Severe osteoporosis: Principles for pharmacological therapy in Mexico.","volume":"17","author":"P Clark","year":"2021","journal-title":"Reumatol Cl\u00ednica Engl Ed."},{"key":"pone.0299673.ref014","author":"CSG","year":"2023","journal-title":"Gu\u00eda para la conducci\u00f3n de estudios de evaluaci\u00f3n econ\u00f3mica para la actualizaci\u00f3n del Compendio Nacional de Insumos para la Salud [Internet]."},{"issue":"5","key":"pone.0299673.ref015","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"AB Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"pone.0299673.ref016","unstructured":"CENETEC. Diagn\u00f3stico y tratamiento de osteoporosis en mujeres posmenop\u00e1usicas. Gu\u00eda de Evidencias y Recomendaciones: Gu\u00eda de Pr\u00e1ctica Cl\u00ednica [Internet]. Available from: http:\/\/www.cenetec-difusion.com\/CMGPC\/GPC-IMSS-673-18\/ER.pdf"},{"issue":"15","key":"pone.0299673.ref017","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"KG Saag","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"pone.0299673.ref018","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"F Cosman","year":"2016","journal-title":"N Engl J Med"},{"issue":"10102","key":"pone.0299673.ref019","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.","volume":"390","author":"BL Langdahl","year":"2017","journal-title":"The Lancet"},{"key":"pone.0299673.ref020","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","article-title":"Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis.","volume":"22","author":"B J\u00f6nsson","year":"2011","journal-title":"Osteoporos Int."},{"key":"pone.0299673.ref021","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","article-title":"Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.","volume":"11","author":"A Parthan","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"pone.0299673.ref022","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s00198-017-3973-8","article-title":"Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.","volume":"28","author":"K Moriwaki","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"pone.0299673.ref023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11657-022-01106-9","article-title":"Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.","volume":"17","author":"R Goeree","year":"2022","journal-title":"Arch Osteoporos"},{"key":"pone.0299673.ref024","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00198-021-05927-1","article-title":"Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan.","volume":"32","author":"H Hagino","year":"2021","journal-title":"Osteoporos Int"},{"key":"pone.0299673.ref025","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00198-020-05780-8","article-title":"Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden.","volume":"32","author":"E S\u00f6reskog","year":"2021","journal-title":"Osteoporos Int"},{"key":"pone.0299673.ref026","author":"SEGOB","year":"2021","journal-title":"EDICI\u00d3N 2021 del Libro de Medicamentos del Compendio Nacional de Insumos para la Salud. [Internet]"},{"issue":"5","key":"pone.0299673.ref027","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","article-title":"Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures","volume":"14","author":"Group S of OFR","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"11","key":"pone.0299673.ref028","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians","volume":"166","author":"Physicians* CGC of the AC of","year":"2017","journal-title":"Ann Intern Med"},{"key":"pone.0299673.ref029","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/BF01623315","article-title":"Cost-effectiveness of fracture prevention in established osteoporosis.","volume":"5","author":"B J\u00f6nsson","year":"1995","journal-title":"Osteoporos Int."},{"key":"pone.0299673.ref030","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00198-019-05064-w","article-title":"Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.","volume":"30","author":"A Svedbom","year":"2019","journal-title":"Osteoporos Int."},{"key":"pone.0299673.ref031","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00198-006-0257-0","article-title":"Cost-effectiveness of the treatment and prevention of osteoporosis\u2014a review of the literature and a reference model.","volume":"18","author":"N Zethraeus","year":"2007","journal-title":"Osteoporos Int."},{"issue":"7","key":"pone.0299673.ref032","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.clinthera.2017.05.348","article-title":"A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture.","volume":"39","author":"CE O\u2019Hanlon","year":"2017","journal-title":"Clin Ther"},{"key":"pone.0299673.ref033","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bone.2013.11.002","article-title":"Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective","volume":"59","author":"A Parthan","year":"2014","journal-title":"Bone"},{"issue":"1","key":"pone.0299673.ref034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-013-9724-8","article-title":"Health technology assessment in osteoporosis","volume":"93","author":"M Hiligsmann","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"pone.0299673.ref035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-009-1032-9","article-title":"Updated fracture incidence rates for the US version of FRAX\u00ae.","volume":"21","author":"B Ettinger","year":"2010","journal-title":"Osteoporos Int"},{"key":"pone.0299673.ref036","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s001980050113","article-title":"Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time.","volume":"9","author":"LJ Melton","year":"1999","journal-title":"Osteoporos Int."},{"key":"pone.0299673.ref037","unstructured":"Cosman F, Oates M, Betah D, Ferrari S, McClung MR. One Year of Romosozumab Followed by One Year of Denosumab Compared With Two Years of Denosumab: BMD and Fracture Results From the FRAME and FRAME Extension Studies. In: Oral presentation (#1055) at 2022 ASBMR annual meetings. Austin, TX;"},{"issue":"2","key":"pone.0299673.ref038","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/M22-0684","article-title":"Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network meta-analysis for the American College of Physicians","volume":"176","author":"C Ayers","year":"2023","journal-title":"Ann Intern Med"},{"issue":"4","key":"pone.0299673.ref039","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"ML Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"5","key":"pone.0299673.ref040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"MR McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0299673.ref041","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fphar.2017.00803","article-title":"Pharmacological therapy of osteoporosis: a systematic current review of literature.","volume":"8","author":"V Pavone","year":"2017","journal-title":"Front Pharmacol"},{"key":"pone.0299673.ref042","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00198-007-0406-0","article-title":"Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world.","volume":"18","author":"H Ideguchi","year":"2007","journal-title":"Osteoporos Int."},{"issue":"24","key":"pone.0299673.ref043","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.","volume":"296","author":"DM Black","year":"2006","journal-title":"Jama"},{"key":"pone.0299673.ref044","author":"Actuaries S of","year":"2010","journal-title":"Mortality and Other Rate Tables [Internet]."},{"issue":"4","key":"pone.0299673.ref045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0272989X06290497","article-title":"Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.","volume":"26","author":"J Hanmer","year":"2006","journal-title":"Med Decis Making"},{"key":"pone.0299673.ref046","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00198-017-4317-4","article-title":"Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures\u2014results from the ICUROS.","volume":"29","author":"A Svedbom","year":"2018","journal-title":"Osteoporos Int."},{"key":"pone.0299673.ref047","author":"SHCP","year":"2023","journal-title":"Portal del Sistema Electr\u00f3nico de Compras Gubernamentales [Internet]."},{"key":"pone.0299673.ref048","author":"Federaci\u00f3n (DOF) DO de la.","year":"2023","journal-title":"ACUERDO n\u00famero ACDO.AS3.HCT.251022\/299.P.DF dictado por el H. Consejo T\u00e9cnico, en sesi\u00f3n ordinaria de 25 de octubre de 2022, relativo a la aprobaci\u00f3n de los Costos Unitarios por Nivel de Atenci\u00f3n M\u00e9dica actualizados al a\u00f1o 2023. [Internet]."},{"key":"pone.0299673.ref049","author":"HGG Gonz\u00e1lez","year":"2018","journal-title":"Tabulador de Cuotas de Recuperaci\u00f3n [Internet]."},{"key":"pone.0299673.ref050","author":"F Carlos-Rivera","year":"2023","journal-title":"Projected frequency and economic burden of incident fragility fractures during 2023 in Mexico"},{"key":"pone.0299673.ref051","article-title":"\u00cdndice Nacional de Precios al Consumidor.","author":"Geograf\u00eda (INEGI) IN de E y","year":"2023","journal-title":"Salud y Cuidado Personall [Internet]."},{"key":"pone.0299673.ref052","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006"},{"key":"pone.0299673.ref053","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00198-021-05951-1","article-title":"Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.","volume":"32","author":"A Singer","year":"2021","journal-title":"Osteoporos Int"},{"key":"pone.0299673.ref054","unstructured":"Chien, HC, Arora, T, Oates, M, McDermott, M, Curtis, JR. Drug utilization patterns of anabolic agents\u2014romosozumab and parathyroid hormone analogues\u2014among postmenopausal women in the U.S., 2019\u20132021. In Vancouver, Canada; 2023."},{"key":"pone.0299673.ref055","author":"CADTH","year":"2022","journal-title":"Romosozumab for the treatment of osteoporosis in postmenopausal women with a history of osteoporotic fracture and who are at very high risk for future fracture. [Internet]"},{"issue":"2","key":"pone.0299673.ref056","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40618-022-01910-7","article-title":"Cost-effectiveness analysis of five drugs for treating postmenopausal women in the United States with osteoporosis and a very high fracture risk","volume":"46","author":"C Luo","year":"2023","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"pone.0299673.ref057","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.","volume":"99","author":"BZ Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T13:33:17Z","timestamp":1738935197000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299673"}},"subtitle":[],"editor":[{"given":"Dengshun","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299673","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}